Moderna, Inc. (MRNA)
| Market Cap | 44.87B |
| Revenue (ttm) | 5.15B |
| Net Income (ttm) | -5.97B |
| Shares Out | 383.24M |
| EPS (ttm) | -15.66 |
| PE Ratio | n/a |
| Forward PE | 32.47 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,355,853 |
| Open | 117.34 |
| Previous Close | 115.95 |
| Day's Range | 114.02 - 119.14 |
| 52-Week Range | 62.55 - 170.47 |
| Beta | 1.54 |
| Analysts | Hold |
| Price Target | 139.80 (+19.42%) |
| Earnings Date | Aug 1, 2024 |
About MRNA
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vac... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 18 analysts, the average rating for MRNA stock is "Hold." The 12-month stock price forecast is $139.8, which is an increase of 19.42% from the latest price.
News
Moderna Receives HHS Grant to Develop a Bird Flu Vaccine
Moderna (MRNA) shares edged higher Tuesday after the biotech firm received a federal grant to develop a vaccine to prevent bird flu in humans.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
NEW YORK , July 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. ("Moderna" or the "Company") (NASDAQ: MRNA). Such investors are advised to conta...
US awards Moderna $176 million to produce bird flu vaccine
The U.S. government has awarded $176 million to Moderna to advance development of its bird flu vaccine, the company said on Tuesday, as concerns rise over a multi-state outbreak of H5N1 virus in dairy...
Moderna gets U.S. government funding for bird-flu vaccine development
Moderna Inc.'s efforts to develop a bird-flu vaccine are getting a boost from the U.S. government, the company said Tuesday.
Moderna Scores Federal Funding For mRNA Bird Flu Vaccine As Pandemic Fears Grow
Moderna has secured $176 million in federal funding to develop mRNA vaccines against a potential bird flu pandemic, the Boston-based company announced Tuesday, a move that could bolster U.S. vaccine s...
Moderna Receives Project Award through BARDA's Rapid Response Partnership Vehicle Consortium to Accelerate Development of mRNA-based Pandemic Influenza Vaccine
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the developm...
UK court gives mixed ruling in Pfizer v Moderna COVID vaccine patents case
London's High Court on Tuesday ruled that one of Moderna's patents relating to technology key to the development of vaccines for COVID-19 was invalid, but that another was valid and had been infringed...
Pfizer And Moderna Vaccines Not Linked To Birth Defects, Study Finds
There is no evidence of major birth defects in babies born to mothers vaccinated against COVID-19 during the first trimester of pregnancy, according to new research published in JAMA Pediatrics on Mon...
Investors Who Lost Money on Moderna, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - MRNA
NEW YORK, NY / ACCESSWIRE / July 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Moderna, Inc. ("Moderna") (NASDAQ:MRNA) concerning possible violations of feder...
An Investigation Has Commenced on Behalf of Moderna, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your MRNA Losses
NEW YORK, NY / ACCESSWIRE / June 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Moderna, Inc. ("Moderna") (NASDAQ:MRNA) concerning possible violations of fede...
Moderna's RSV vaccine gets positive opinion from EU advisory panel
The vaccine has already won approval from the FDA
EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Marketing Authorization Of Moderna's RSV Vaccine, mRESVIA(R)
CAMBRIDGE, MA / ACCESSWIRE / June 28, 2024 / Moderna, Inc. (Nasdaq:MRNA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a ...
Vaccine makers' stocks fall as CDC advisers shift RSV-shot recommendations
Shares of vaccine makers Pfizer Inc., GSK PLC and Moderna Inc. dropped Wednesday as advisers to the Centers for Disease Control and Prevention shifted their recommendations for who should be vaccinate...
ATTENTION Moderna, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Moderna, Inc. ("Moderna") (NASDAQ:MRNA) concerning possible violations of fede...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. ("Moderna" or the "Company") (NASDAQ:MRNA). Such investors are advised to cont...
Why Is Moderna Stock Trading Lower On Wednesday?
The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practice will meet this week to consider and recommend who should get respiratory syncytial virus (RSV), influenza, ...
Moderna's stock falls after data shows biotech's RSV vaccine trails rivals after 18 months
Moderna Inc.'s stock fell 6.4% Wednesday, after the company said that its respiratory syncytial virus, or RSV, shot showed 50% efficacy in preventing the illness after 18 months.
Moderna says its RSV shot is 50% effective across a second season
Moderna Inc respiratory syncytial virus (RSV) shot mRESVIA showed 50% efficacy in preventing RSV after 18 months, the drugmaker said on Wednesday.
Moderna, Inc. (MRNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, NY / ACCESSWIRE / June 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA). In...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. (“Moderna” or the “Company”) (NASDAQ: MRNA). Such investors are advised to con...
Moderna says new-generation COVID vaccine more effective than Spikevax
Moderna Inc. MRNA, -0.45% said Thursday a Phase 3 trial of its next-generation COVID-19 vaccine met its main goal and showed higher efficacy in adults compared to its original vaccine dubbed Spikevax....
Moderna's next-gen COVID vaccine shows non-inferiority to current shot
Moderna said on Thursday its next-generation COVID-19 vaccine candidate met its main goal in a late-stage study by showing vaccine efficacy that was non-inferior compared with the company's commercial...
Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company's Next Generation COVID-19 Vaccine
mRNA-1283 met its primary vaccine efficacy endpoint in a Phase 3 trial, demonstrating non-inferior vaccine efficacy against COVID-19 compared to Spikevax® in participants 12 years of age and older Hig...
Moderna Submits Updated COVID-19 Jab to FDA for Review
Moderna, Inc. announced that it has submitted an application to the FDA seeking approval of its Spikevax 2024-2025 formula, targeting the COVID-19 variant JN.1, the latest variant of the novel virus r...
Moderna CEO on side effects of combination vaccine
“We think it's a very good tradeoff for consumers and doctors,” Moderna CEO Stephane Bancel said on the side effects of the company's combination vaccine that targets both Covid-19 and the flu.